Bod Science Limited
BOD.AX
BOD.AXBod Science Limited
Australian Securities Exchange0.02
AUD
- -
- -
ISIN
AU0000181331
Return %
Stock
S&P500
1Y
-85.00
6.57
3Y
-94.48
22.75
5Y
-94.00
93.55
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Ms. Joanne Patterson
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 377 New South Head Road Double Bay NSW Australia 2028
- IPO Date
- Oct 26, 2016
- Website
- bodscience.com
- Similar Companies
- Business
- Bod Science Limited operates as a cannabis focused drug development and product innovation company in Australia, the United Kingdom, the European Union, and the United States. The company operates through three segments: Medical, Over The Counter (OTC) Cannabidiol/Hemp, and OTC Herbals. It engages in the development and manufacture of cannabidiol and hemp products for consumers; and development and distribution of therapeutics medicinal cannabis products for medical markets. The company provides Flexofytol, an anti-inflammatory derived from a scientifically validated and clinically trialed turmeric extract that helps in improving joint health, limiting the ageing of cartilage, and reducing inflammation caused by mild arthritis; and Sedistress, a passion flower extract that reduces the symptoms of stress, anxiety, and insomnia. The company was formerly known as Bod Australia Limited and changed its name to Bod Science Limited in December 2022. Bod Science Limited was incorporated in 2014 and is based in Double Bay, Australia.